AlphaFold predicted structure
PTRH2 · Q9Y3E5

Mean pLDDT
83.9/ 100
Confident
179 residues
Confidence breakdown
- Very high(≥ 90)59%
- Confident(70–90)16%
- Low(50–70)16%
- Very low(< 50)9%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
peptidyl-tRNA hydrolase 2
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Ataxia and cerebellar anomalies - narrow panel
BIALLELIC, autosomal or pseudoautosomalDDG2P
BIALLELIC, autosomal or pseudoautosomalHereditary ataxia with onset in adulthood
BIALLELIC, autosomal or pseudoautosomalHereditary neuropathy or pain disorder
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalHereditary neuropathy
BIALLELIC, autosomal or pseudoautosomalMonogenic hearing loss
BIALLELIC, autosomal or pseudoautosomalMitochondrial disorders
neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 1
neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset
intellectual disability, autosomal dominant 56
cerebellar ataxia
Global developmental delay
Hearing impairment
hereditary disease
diabetes mellitus
type 2 diabetes mellitus
neoplasm
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Peptidyl-tRNA hydrolase 2, mitochondrial
Peptidyl-tRNA hydrolase which releases tRNAs from the ribosome during protein synthesis (PubMed:14660562). Promotes caspase-independent apoptosis by regulating the function of two transcriptional regulators, AES and TLE1
PTRH2 · Q9Y3E5

Mean pLDDT
83.9/ 100
Confident
179 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0